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1. Introduction
Advanced melanoma is a highly aggressive tumor with a low response rate to the majority of
pharmacological agents.
Among conventional cytotoxic chemotherapies, dacarbazine (DTIC) is the only FDA-ap‐
proved alkylating agent, at present; its clinical efficacy is pretty low with 5–10% responsive‐
ness, which is generally short-lived. Carmustine, temozolomide and other chemotherapic
agents (taxanes and platinum-analogs) showed similar efficacy in metastatic settings [1, 2].
Adjuvant immunotherapy for stage III melanoma is mainly based on interferon-α2b (IFN-α2b)
even if its efficacy is quite limited. In fact, only about the 20% of patients showed an improve‐
ment in relapse-free survival as demonstrated in randomized observation-controlled trials
without a clear effect on overall survival [3]. FDA approved high-dose interleukin-2 (IL-2) for
the treatment of advanced stage melanoma, on the basis of its ability to elicit durable responses
in a small percentage of patients [4, 5]. However, the durable response rate is only 10-20% and
toxicities associated with IL-2 are quite severe.
Recently, molecular targeted therapies have radically changed the management of metastat‐
ic melanoma. Anti-CTLA-4 monoclonal antibodies (Ipilimumab) and B-Raf inhibitors are
the first examples of this new kind of drugs, the firsts approved with both overall survival
and  progression-free  survival  benefits  in  respect  of  the  standard  chemotherapic  agent
dacarbazine [6-10].
Ipilimumab targets the anti-cytotoxic T-lymphocyte antigen-4, a key immune-checkpoint
molecule that down-regulates some pathways of T-cell activation. Ipilimumab inactivating the
CTLA-4 inhibitory signal, enhance the immune system response against melanoma cells.
Several randomized phases II and III trials demonstrated a statistically significant improve‐
ment in overall survival in patients with metastatic melanoma treated with Ipilimumab alone
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or in combination with dacarbazine. The efficacy of Ipilimumab was confirmed both in treated
and untreated metastatic melanoma patients [6, 9, 11]. Furthermore, re-treatment with
Ipilimumab can re-establish disease control in a percentage of patients who progress after
achieving an objective response or stable disease after the first treatment course [6, 9, 11-13].
As a consequence of this peculiar mechanism of action, Ipilimumab may determine the
development of autoimmune conditions and exacerbate a series of immune-related adverse
events, which will be described in the next section of this review.
Vemurafenib is a low molecular weight molecule (489.9 Da), orally available, which belongs
to the new generation inhibitors of B-Raf as well as of other members of the RAF kinase
family (including the products of ARAF, BRAF and CRAF genes). The BRAF protein is a
part  of  the RAS/RAF/MEK/ERK signaling pathway, which is  a key regulator of  melano‐
ma cell growth. In cells expressing the pro-oncogenic BRAF-V600E, BRAF-V600D and BRAF-
V600R genes, Vemurafenib inhibits both phosphorylated ERK (pERK) and pMEK in a dose-
dependent  manner,  resulting  in  a  reduction  of  tumour  growth  and  even  in  tumour
regression in in vitro studies and xenograft transplant models. Several clinical trials have
confirmed and extended these preclinical observations and, to date, RAF inhibitors represent
the  emerging  standard  of  care  for  metastatic  melanoma  harboring  the  BRAF-V600E
mutation,  with  clinical  responsiveness  in  more  than  90%  of  these  patients  [1,  14].  In
particular,  results  from a  phase  III  clinical  trial  of  patiente  expressing  the  BRAF-V600E
mutated isoform affected by unresectable or metastatic melanoma showed a median overall
survival significantly higher for Vemurafenib-treated patients,in comparison to those treated
with dacarbazine (13.2 vs 9.9 months, respectively).
Even if the toxicity of this treatment is normally considered to be acceptable, Vemurafenib
triggers the onset of a wide spectrum of systemic and cutaneous toxicities which can impact
patient’s quality of life in a significant way [15-17]. The adverse effects, which will be detailed
later, are dose-dependent and related to the alteration of the cell-signaling pathway in response
to B-Raf inhibition in cells expressing the wild-type BRAF gene [18].
2. Ipilimumab toxicities
The onset of immune-related adverse events (irAEs) during the treatment with Ipilimumab is
consequent to action on the immune system. Actually, CTLA-4 blockage removes CTLA4-
mediated downregulation of the immune response, leading thus to a large spectrum of
autoimmune–inflammatory side effects with a dose-dependent mechanism [19]. These irAEs
are described both at the currently approved 3mg/kg dose and at the investigational 10mg/kg
dose and may affect a number of organs and systems, including the eye, the skin, the gut and
the endocrine system.
In a retrospective analysis of phase I–III Ipilimumab trials on patients with advanced mela‐
nomas, the occurrence of irAEs of any grade was a quite common phenomenon, regarding
about 60% of the patients [20]. Nevertheless, Ipilimumab can be considered a safe drug: irAEs-
related deaths occurred only in about 1% of treated patients [20]. In these trials, the most
common immune side effects were represented by enterocolitis, dermatitis, hepatitis, hypo‐
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physitis, and uveitis, usually with an early onset. More recent data obtained on an Italian multi-
centric expanded-access cohort reported an occurrence of irAEs of any grade in 33% of treated
patients, with a median time of onset of 5 weeks. Most irAEs were low grade, whereas grade
3/4 irAEs were described in 6% of the cases and were most commonly represented by diarrhea,
liver toxicity and fatigue/asthenia [21].
IrAE Grade 1 Grade 2 Grade 3 Grade 4
Skin Toxicity
Mild to moderate
localized rash or
pruritus;
papules/pustules
covering
<10%–30% of the body
surface
Non localized rash
(diffuse, ≥50% of skin
surface)
Intense and widespread
(>30% of body surface)
skin rash; skin
sloughing of <10%–30%
of the body surface;
epidermal or mucus
membrane detachment
Stevens–Johnson
syndrome, toxic
epidermal necrolysis, or
rash complicated by
full-thickness dermal
ulceration, or necrotic,
bullous, or hemorrhagic
manifestations
Diarrhea
Increase of <4 stools
per day over baseline;
mild increase in ostomy
output compared with
baseline
Increase of 4–6 stools
per day
over baseline;
Intra venous fluids
indicated <24 hours;
moderate increase in
ostomy output
compared to baseline;
not interfering with
activities of daily
living
Increase of ≥7 stools per
day over baseline;
incontinence;
Intra venous fluids
>24hours;
hospitalization; severe
increase in ostomy
output compared with
baseline; interfering
with activities of daily
living
Life-threatening
diarrhea, causing severe
hemodynamic
alterations and even
collapse
Liver toxicity
Asymptomatic or mild
symptoms; clinical or
diagnostic
observations only;
intervention not
indicated
AST or ALT >2.5
to ≤5.0 × ULN and/or
total bilirubin >1.5
to ≤3.0× ULN
AST or ALT >5× ULN
and/or
total bilirubin >3.0×
ULN
Moderate to severe
encephalopathy with
abnormal plasma levels
of ammonia, bilirubin,
lactic dehydrogenase,
and alkaline
phosphatase
Endocrine toxicity
Asymptomatic;
clinical or diagnostic
observations only;
intervention not
indicated
Moderate symptoms;
medical intervention
indicated
Severe symptoms;
hospitalization
indicated
Adrenal crisis: severe
dehydration,
hypotension, or shock.
Life-threatening
consequences
Modified from Weber J, et al. J Clin Oncol 30 (21), 2012: 2691-2697[23].
Table 1. Most common Immunorelated Edverse events and their grade:
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IrAE Grade 1 Grade 2 Grade 3 Grade 4
Skin Toxicity
Antihistamines and
topical
corticosteroids; if no
response, consider oral
corticosteroids
Antihistamines and
topical
corticosteroids if no
response,
consider oral
corticosteroids
High-dose systemic
corticosteroid therapy
High-dose systemic
corticosteroid therapy;
antibiotics if indicated and
definitive discontinuation
of Ipilimumab
Diarrhea
Anti-diarrhea drugs,
loperamide and
diphenoxylate
Patient hydration
Anti-diarrhea drugs
Loperamide and
diphenoxylate.
Patient hydration
Hospitalization, patients
hydration and systemic
corticosteroids
Hospitalization, patient
hydration, and systemic
corticosteroids.
Definitive discontinuation
of Ipilimumab
Liver toxicity Monitoring of LFTs
Withhold Ipilimumab
dose and check
LFTs every day for 3
consecutive days;
if LFT improvement to
grade 1, resume routine
monitoring
of LFTs and continue
Ipilimumab
If no improvement in the
LFTs, administer
corticosteroid
treatment and skip the
next Ipilimumab dose
until event
resolves
Withhold Ipilimumab
dose and check LFTs
every day for 3
consecutive days;
if LFT improvement to
grade 1, resume routine
monitoring of
LFTs and continue
Ipilimumab
If no improvement in
LFTs, administer
corticosteroid treatment
and skip the next
Ipilimumab dose until
event resolves
High dose of intravenous
corticosteroids
Definitive discontinuation
of Ipilimumab
Endocrine toxicity
Abnormal endocrine
workup, grade 1 or 2
endocrine toxicity without
adrenal crisis
May resolve
spontaneously
If no spontaneous
resolution, consider low–
moderate dose
Of systemic
corticosteroids
Consider temporary
Ipilimumab suspension
Symptoms suggestive
of hypophysitis require
prompt
corticosteroid therapy.
Temporary Ipilimumab
suspension
Intravenous
corticosteroids
Hormone replacement
Hydration
Electrolyte replacement
Temporary Ipilimumab
suspension
Intravenous
corticosteroids
Hormone replacement
Hydration
Electrolyte replacement
Definitive discontinuation
of Ipilimumab
Modified from Weber J, et al. J Clin Oncol 30 (21), 2012: 2691-2697 [23].
Table 2. Most common immunorelated adverse events and their management:
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In phase I-III studies, irAE resolution time varied from 4.3 to 7.7 weeks, whereas in patients
included in the expanded-access projects ranged from 0.1 to 11.1 weeks (median 1.7 weeks).
When grade 3/4 irAE were separately analyzed the median resolution time was 1.1 weeks
(range, 0.1–3.4 weeks) [20, 21]. Despite some early findings, no relationship seems to exist
between clinical benefit and irAEs onset in treated patients.
Grade 1/2 events take advantage from symptomatic treatments and the use of topical steroids,
whereas early administration of high-dose systemic corticosteroids is mandatory for the right
management of grade 3/4 irAEs. Specific guidelines to manage irAEs are available [19, 22]. In
literature are available guidelines to manage Ipilimumab side effects (see Table 1 and 2) [23].
3. Cutaneous side effects from Ipilimumab
Systemic side effects from Ipilimumab are usually dose-related. However, the incidence and
severity of pruritus or skin reactions appear independent of Ipilimumab dosage, as demon‐
strated by a meta-analysis of the studies in which Ipilimumab was administered as mono‐
therapy at different doses (3 mg/kg vs 10 mg/kg),
Commonly used targeted anticancer agents (e.g. erlotinib, cetuximab, panitumumab, vande‐
tanib, pertuzumab) usually induce a characteristic papulopustular (acneiform) rash in 68% to
75% of treated patients. Conversely, Ipilimumab-induced maculo-papular rash are more
similar to those commonly seen with traditional drugs (ie, antibiotics, non steroidal anti-
inflammatory drugs) or shows clinical characteristics mimicking atopic dermatitis [22].
From a recent meta-analysis performed on 19 studies from 1998-2011, which included several
trials testing Ipilimumab (as monotherapy or in combination at various doses in randomized
multi-arm and single-arm studies) [24], emerged that the overall incidence of all-grade rash
was 24.3%. The overall incidence of high-grade rash was 2.4%, with a relative risk ranging
from 0.7% to 11.8%. Interestingly, among 320 patients receiving 3 mg/kg and 440 receiving 10
mg/kg, there was no significant difference in terms of incidence of all-grade or high-grade rash
between doses [24]. Skin irAEs have a shorter time of onset than those affecting other sites and
usually develop 3-4 weeks after Ipilimumab initiation.
In our series of 57 patients treated with Ipilimumab, the incidence of cutaneous side effects
was 10% (any grade). Ipilimumab-related skin lesion were erythematous, edematous or
maculo-papular, often located on the trunk and extremities (Figure 1); vasculitic and purpuric
lesions were also observed. Pruritus was present in almost half of the patients who showed
skin reactions [unpublished data]. Some literature reports suggest that rash can coincide with
the regression of subcutaneous disease and may be especially pronounced around nevi,
suggesting the presence of an underlying inflammatory response against melanocytes [25-27].
The onset of vitiligo-like lesions during Ipilimumab treatment is also a finding related to an
immune activation status of the host, and was a relatively common event in our experience
[personal unpublished data], as well as in other case reports [28].
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From a histological point of view, skin biopsies of Ipilimumab-related skin lesions showed a
perivascular inflammatory infiltrate in the superficial dermis that extend to the epidermis with
CD4+ and CD8+ T cells that are CD3+. Eosinophils may also be present [24-27].
4. Vemurafenib toxicities
Even if Vemurafenib is generally a safe and well-tolerated drug, a wide spectrum of toxic
effects has been described [14-18, 29, 30]. The most common one is represented by arthralgia,
which occurs in about 60% of patients. Most cases are mild to moderate, but about 5% of
patients treated with Vemurafenib experienced a grade 3 arthralgia [14, 29]. These latter cases
can be managed conservatively with non-steroidal anti-inflammatory drugs and acetamino‐
phen; however, severe cases may require a short course of steroid treatment [31]
Figure 1. Erythemato-edematous rash in a patient treated with Ipilimumab
Liver enzymes should be monitored, since elevated liver enzymes have been documented in
about 20% of treated patients;, usually resolving with a treatment suspension [14, 29, 31].
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Only a relatively small percentage of patients (approximately 20%) experience nausea, which
is normally responsive to oral antiemetics [31].
Quite unusual but potentially life-threatening side effects are related to alterations of the
cardiac rhythm, including the prolongation of cardiac repolarization and arrhythmia, which
occurs in about 8% of patients. Hence, the monitoring of cardiac activity is mandatory in all
Vemurafenib-treated patients; however, the occurrence of absolute QTc values >500 ms [29,
31, 32] that require prompt clinical management is quite rare.
5. Cutaneous side effects from Vemurafenib
Cutaneous reactions are the most common side effects described during Vemurafenib
treatment and impact significantly on patient’s quality of life [15-17, 29]. As expected from the
experience collected with other molecular targeted therapies, skin toxicity is related to the
alteration of the wild-type BRAF signaling [18].
The cutaneous adverse reactions affect a percentage of treated patients from 75 to 90%, without
difference of age and sex and can be classified according to the reaction pattern and time of
appearance as follows:
5.1. Rash
Literature data report the onset of a maculo-papular eruption in about 50% of treated patients
[14, 16, 18, 29]. Also in our experience, rash was the earliest and most frequent cutaneous side
effect during Vemurafenib treatment (48% of treated patients of our series). From a clinical
point of view, this rash could be similar to other drug-related exanthemas and it is character‐
ized by the onset of maculae and follicular papules mainly distributed on the trunk and limbs
(Figure 2); the head region is generally spared. Rush appears after a median time of 11 days
(range 7-55 days), it is generally self-limiting and spontaneously resolve after a median of 18
days from the onset (range 2-95). In the majority of cases, it is asymptomatic, even if some
patients reported pruritus [personal unpublished data].
Cases that underwent skin biopsy show an inflammatory lympho-histiocytic lichenoid
infiltrate, even if keratinocytes activation should be observed [18]. The origin of this maculo-
papular eruption is still unclear; however these features can explain the usefulness of topical
steroids, as well as the anecdotic finding that rush did not occurred in patients receiving
concomitant steroids for medical treatments related to other diseases.
Because of the self-limiting nature of this side effect, we recommend the routinely use of topical
emollients; steroids should be limited to symptomatic cases. Patients also have to be informed
about the frequency and benignity of this rash; however, persistent or clinically atypical
exanthemas should be referred to an experienced dermatologist to avoid the risk of Steven-
Johnson Syndrome /Toxic Epidermal Necrolysis (SJS/TEN) [33, 34].
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Figure 2. Maculae and follicular papules distributed on limbs in a patients treated with Vemurafenib
5.2. Warts
Viral warts represent the second most frequent cutaneous side effect of Vemurafenib [15-17]
which affects about 41% of patients in our experience; median time of onset is 50 days from
the initiation of treatment. Warts affect mainly the regions of the head and neck, less frequently
the trunk and limbs (Figure 3). In our casistics, viral warts were the first cutaneous side effect
in 13.7% of patients [unpublished data].
Histologically, Vemurafenib-dependent warts were indistinguishable from common viral
warts [15, 19]; standard wart treatments (e.g. cryosurgery, keratolytic solutions, and diather‐
mic coagulation) usually are very effective.
5.3. Hyperkeratosis
In a percentage of Vemurafenib-treated patients, the induction of a keratinocytic hyperprolif‐
eration without signs of apoptosis results in an increased epidermal thickness [28]. Plantar
hyperkeratosis occurs mainly in areas under physical pressure, whereas diffuse hyperkeratotic
follicular papules are observed mainly in the lower limbs and forearms (Figure 4). In our
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experience, the median onset time of localized and diffuse hyperkeratosis is 44 and 31 days,
respectively.
Topical keratolytic and emollient treatment can reduce hyperkeratosis, even if a complete
resolution of this side effect was observed only after Vemurafenib discontinuation.
Figure 4. Plantar hyperkeratosis occurred in areas under physical pressure during Vemurafenib treatment
5.4. Photosensitivity
Photosensitivity is another common phenomenon in Vemurafenib-treated patients. Even if
this side effect does not represent a life-threatening condition, it can impact on patients’ quality
of life and could be difficult to manage [14, 17, 29, 30]. Painful sunburns are an early phenom‐
enon and may occur after few minutes of sun exposure; UVA seems to play a more prominent
role than UVB. In our experience, sunburns were observed in 14% of patients, also after a few
days of treatment (Figure 5). Patient phototype and intensity of sun exposure can concur in
the onset of this phenomenon. In our series, all patients who developed sunburns during
Vemurafenib treatment showed a photo type II [personal unpublished data].
Figure 3. Disseminated viral warts in a patient treated with Vemurafenib
Toxicities of New Drugs for Melanoma Treatment and their Management
http://dx.doi.org/10.5772/59860
287
Sun protection is mandatory in Vemurafenib-treated patients, and should be started together
with BRAF inhibitor.
Actinic conjunctivitis is also described as an early as well as a very late side effect.
 
Figure 5. Painful sunburns developed after a few days of Vemurafenib treatment
5.5. Effluvium and hair changes
In our experience, effluvium occur in 17% of patient, after a median time of 88 days, usually
without complete hair loss. Moreover, some patients experience a curling and ticking of the
hair. Hair changes belong to the late onset side effects. All these phenomena could be explained
by a paradoxical up-regulation of MAPK signaling [35-37].
5.6. Hands oedema and urticaria
A less frequent skin toxicity is represented by localized hand oedema, that developed in a few
patients as an early side effect, usually within a month from the beginning of the treatment, in
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the absence of other signs of localized or diffuse oedema. In these patients, laboratory tests did
not show renal toxicity or hypoalbuminemia. Morevover, cases of urticarial episodes during
the Vemurafenib treatment are described, particularly in patients with a personal history of
atopia; normally, these episodes spontaneously resolve without drug suspension, and, hence,
the relationship between Vemurafenib and urticaria remains to be ascertained [15-17, 29].
5.7. Skin cancer
The first reports of skin toxicity obtained from phase I-III clinical trials and expanded access
studies showed the onset of squamous cell carcinomas (SCCs) in up to 31% of Vemurafenib-
treated patients [30]. However, a pathology review of all lesions excised in phase II study
revealed that 90% of reported SCCs were keratoacanthomas and the remaining 10%, well-
differentiated squamous cell carcinomas. More recent reports stated that incidence of SCCs
and keratoacanthomas is about 14-18%, respectively [18].
Literature data hypothesize that keratoacanthomas and SCCs develop as a consequence of pre-
existing precancerous RAS mutations in keratinocytes of sun-exposed areas that are then
activated by Vemurafenib through a paradoxical up-regulation of MAPK signaling [30, 35].
This mechanism could explain the keratinocytes proliferation that leads to keratosis pilaris-
like lesions, palmo-plantar hyperkeratosis and hair changes in Vemurafenib-treated patients;
notably, the same side effects are also observed during treatment with sorafenib and MEK
inhibitors. Along this line, chemoprevention of cutaneous SCCs by the subministration of
systemic retinoids has been reported to be successful in Vemurafenib-treated [28]. In our
experience, also topical retinoid can significantly reduce the hyperkeratosis, with lower side
effects (unpublished data).
6. Toxicity profiles of emerging BRAF inhibitors
The second-generation BRAFV600 inhibitor Dabrafenib has an acceptable safety profile. The
percentage of patients that experience treatment-related side toxicities is lower respect to
Vemurafenib and drug-related adverse events of grade ≥2 occur in about 5% of patients.
Clinical trials with Dabrafenib and Vemurafenib show several differences in type, grade and
frequencies of toxicities [15-18, 38, 39]. Cutaneous toxicities such as rash, hyperkeratosis and
the development of non-melanoma skin cancers are less frequent in Dabrafenib-treated
patients than inr those treated with Vemurafenib. In particular, skin carcinomas occur in 19%
of patients treated with Vemurafenib as opposed to 5% during treatment with dabrafenib.
Patients included in the phase I and II trials with Dabrafenib do not experienced photosensi‐
tivity, which could therefore be considered a Vemurafenib-specific toxicity.
Non-cutaneous toxicities such as arthralgia and fatigue also occur at an increased rate and
grade for patients treated with Vemurafenib, whereas pyrexia is a specific toxicity seen with
dabrafenib. The mechanisms underlying Dabrafenib-associated pyrexia are poorly under‐
stood and require further investigation. However, this condition can be successfully treated
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with steroids. No patient included in clinical trials with Dabrafenib experience liver toxicity
[38, 39].
The increased incidence of high class toxicities scored with Vemurafenib than with Dabrafenib
is likely to be explained by a number of factors, including differences in drug dosage (the
administered dose for Dabrafenib is lower than for Vemurafenib), RAF inhibitor potency,
histopathologic assessment of cutaneous lesions, classification and reporting of toxicity.
Moreover, the differences in phototype and exposure to exogenous risk factors for skin
carcinomas of the different geographic populations enrolled in these studies could also play
an important role.
7. Conclusions
The efficacy of new drugs for the treatment of metastatic melanoma is accompanied by a new
spectrum of toxicities, very different from those caused by conventional chemotherapy, but
not less important. Therefore, it is crucial that clinicians develop the necessary skills for the
early detection and management of these toxicities, in order to limit the need of interruption
or suspension of these treatment and to offer the best chance of disease control.
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